{"PubmedBookArticle": [], "PubmedArticle": [{"MedlineCitation": {"KeywordList": [["ACEI", "ARB", "SARI", "age", "coronavirus", "hypertension"]], "SpaceFlightMission": [], "InvestigatorList": [], "OtherAbstract": [], "OtherID": [], "CitationSubset": ["IM"], "GeneralNote": [], "PMID": "32764907", "DateCompleted": {"Year": "2020", "Month": "08", "Day": "13"}, "DateRevised": {"Year": "2020", "Month": "12", "Day": "10"}, "Article": {"ArticleDate": [{"Year": "2020", "Month": "07", "Day": "21"}], "Language": ["eng"], "ELocationID": ["10.2147/CIA.S261516"], "Journal": {"ISSN": "1178-1998", "JournalIssue": {"Volume": "15", "PubDate": {"Year": "2020"}}, "Title": "Clinical interventions in aging", "ISOAbbreviation": "Clin Interv Aging"}, "ArticleTitle": "COVID-19: The Influence of ACE Genotype and ACE-I and ARBs on the Course of SARS-CoV-2 Infection in Elderly Patients.", "Pagination": {"StartPage": "1231", "EndPage": "1240", "MedlinePgn": "1231-1240"}, "Abstract": {"AbstractText": ["Since the beginning of 2020, the whole world has been struggling with the pandemic of Coronavirus Disease 2019 (COVID-19) caused by a novel coronavirus SARS-CoV-2. The SARS-CoV-2 infection depends on ACE2, TMPRSS2, and CD147, which are expressed on host cells. Several studies suggest that some single nucleotide polymorphisms (SNPs) of ACE2 might be a risk factor of COVID-19 infection. Genotypes affect ACE2 structure, its serum concentration, and levels of circulating angiotensin (1-7). Moreover, there is evidence that ACE genotype affects the outcomes of acute respiratory distress syndrome (ARDS) treatment, the most severe consequence of SARS-CoV-2 infection. COVID-19 morbidity, infection course, and mortality might depend on ACE D allele frequency. The aim of this narrative review was to analyze and identify the mechanisms of ACE-I and ARBs with particular emphasis on angiotensin receptors and their polymorphism in the light of COVID-19 pandemic as these medications are commonly prescribed to elderly patients. There is no direct evidence yet for ACE-I or ARBs in the treatment of COVID-19. However, for those already taking these medications, both the European Society of Cardiology and the American College of Cardiology recommend continuing the treatment, because at present, there is no clear clinical or scientific evidence to justify the discontinuation of ACE-I or ARBs. Individualized treatment decisions should be based on the clinical condition and co-morbidities of each patient."], "CopyrightInformation": "\u00a9 2020 Sie\u0144ko et al."}, "AuthorList": [{"Identifier": ["0000-0001-8141-7489"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Surgery and Transplantology, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Sie\u0144ko", "ForeName": "Jerzy", "Initials": "J"}, {"Identifier": ["0000-0003-4870-0156"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of General Surgery and Transplantology, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Kotowski", "ForeName": "Maciej", "Initials": "M"}, {"Identifier": ["0000-0001-5455-8315"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacology and Phytochemistry, Institute of Natural Fibers and Medicinal Plants, Poznan, Poland."}], "LastName": "Bogacz", "ForeName": "Anna", "Initials": "A"}, {"Identifier": ["0000-0002-0807-8510"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Lechowicz", "ForeName": "Kacper", "Initials": "K"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pharmacokinetics and Monitored Therapy, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Dro\u017cd\u017cal", "ForeName": "Sylwester", "Initials": "S"}, {"Identifier": ["0000-0001-7377-4566"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Physiology, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Rosik", "ForeName": "Jakub", "Initials": "J"}, {"Identifier": ["0000-0003-4190-8851"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Civil Engineering and Architecture, West Pomeranian University of Technology in Szczecin, Szczecin, Poland."}], "LastName": "Sietnicki", "ForeName": "Marek", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Pediatrics, Endocrinology, Diabetology, Metabolic Diseases and Cardiology, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Sie\u0144ko", "ForeName": "Magdalena", "Initials": "M"}, {"Identifier": ["0000-0001-8430-1369"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Anaesthesiology, Intensive Therapy and Acute Intoxications, Pomeranian Medical University in Szczecin, Szczecin, Poland."}], "LastName": "Kotfis", "ForeName": "Katarzyna", "Initials": "K"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "New Zealand", "MedlineTA": "Clin Interv Aging", "NlmUniqueID": "101273480", "ISSNLinking": "1176-9092"}, "SupplMeshList": ["Bestrophinopathy"], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Aged"}, {"QualifierName": [], "DescriptorName": "Animals"}, {"QualifierName": [], "DescriptorName": "Betacoronavirus"}, {"QualifierName": [], "DescriptorName": "COVID-19"}, {"QualifierName": [], "DescriptorName": "Comorbidity"}, {"QualifierName": ["genetics", "therapy"], "DescriptorName": "Coronavirus Infections"}, {"QualifierName": [], "DescriptorName": "Eye Diseases, Hereditary"}, {"QualifierName": [], "DescriptorName": "Gene Frequency"}, {"QualifierName": [], "DescriptorName": "Genotype"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": [], "DescriptorName": "Pandemics"}, {"QualifierName": ["genetics", "therapy"], "DescriptorName": "Pneumonia, Viral"}, {"QualifierName": [], "DescriptorName": "Retinal Diseases"}, {"QualifierName": [], "DescriptorName": "SARS-CoV-2"}], "CoiStatement": "The authors report no conflicts of interest in this work."}, "PubmedData": {"ReferenceList": [{"ReferenceList": [], "Reference": [{"Citation": "Cui J, Li F, Shi Z-L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019;17(3):181\u2013192. doi:10.1038/s41579-018-0118-9", "ArticleIdList": ["10.1038/s41579-018-0118-9", "PMC7097006", "30531947"]}, {"Citation": "Wang L, Zhang Y. Animal coronaviruses: a brief introduction In: Wang L. (eds) Animal Coronaviruses. Springer Protocols Handbooks. Humana Press, New York, NY. doi:10.1007/978-1-4939-3414-0_1", "ArticleIdList": ["10.1007/978-1-4939-3414-0_1"]}, {"Citation": "Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869\u2013889. doi:10.1016/j.idc.2019.07.001", "ArticleIdList": ["10.1016/j.idc.2019.07.001", "PMC7127569", "31668196"]}, {"Citation": "Nassar MS, Bakhrebah MA, Meo SA, Alsuabeyl MS, Zaher WA. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: epidemiology, pathogenesis and clinical characteristics. Eur Rev Med Pharmacol Sci. 2018;22(15):4956\u20134961. doi:10.26355/eurrev_201808_15635", "ArticleIdList": ["10.26355/eurrev_201808_15635", "30070331"]}, {"Citation": "Yu P, Zhu J, Zhang Z, Han Y. A familial cluster of infection associated with the 2019 novel coronavirus indicating possible person-to-person transmission during the incubation period. J Infect Dis. 2020;221(11):1757\u20131761. doi:10.1093/infdis/jiaa077", "ArticleIdList": ["10.1093/infdis/jiaa077", "PMC7107453", "32067043"]}, {"Citation": "Kotfis K, Skonieczna-Zydecka K. COVID-19: gastrointestinal symptoms and potential sources of 2019-nCoV transmission. Anaesthesiol Intensive Ther. 2020. doi:10.5114/ait.2020.93867", "ArticleIdList": ["10.5114/ait.2020.93867", "PMC10176516", "32200613"]}, {"Citation": "Gu J, Han B, Wang J. COVID-19: gastrointestinal manifestations and potential fecal\u2013oral transmission. Gastroenterology. 2020;158(6):1518\u20131519. doi:10.1053/j.gastro.2020.02.054", "ArticleIdList": ["10.1053/j.gastro.2020.02.054", "PMC7130192", "32142785"]}, {"Citation": "WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Interim guidance. 2020. \nAvailable from:\nhttps://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. Accessed March13, 2020."}, {"Citation": "Kotfis K, Williams Roberson S, Wilson J, Pun BT, Ely EW. COVID-19: what do we need to know about ICU delirium during the SARS-CoV-2 pandemic? Anaesthesiol Intensive Ther. 2020;52(2):132\u2013138. doi:10.5114/ait.2020.95164", "ArticleIdList": ["10.5114/ait.2020.95164", "PMC7667988", "32419438"]}, {"Citation": "Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176. doi:10.1186/s13054-020-02882-x", "ArticleIdList": ["10.1186/s13054-020-02882-x", "PMC7186945", "32345343"]}, {"Citation": "Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus\u2013infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061. doi:10.1001/jama.2020.1585", "ArticleIdList": ["10.1001/jama.2020.1585", "PMC7042881", "32031570"]}, {"Citation": "Kukla M, Skonieczna-\u017bydecka K, Kotfis K, et al. COVID-19, MERS and SARS with concomitant liver injury\u2014systematic review of the existing literature. J Clin Med. 2020;9(5):5. doi:10.3390/jcm9051420", "ArticleIdList": ["10.3390/jcm9051420", "PMC7290752", "32403255"]}, {"Citation": "Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239. doi:10.1001/jama.2020.2648", "ArticleIdList": ["10.1001/jama.2020.2648", "32091533"]}, {"Citation": "Conthe P, M\u00e1rquez Contreras E, Aliaga P\u00e9rez A, et al. Treatment compliance in chronic illness: current situation and future perspectives. Rev Clin Esp. 2014;214(6):336\u2013344. doi:10.1016/j.rce.2014.03.008", "ArticleIdList": ["10.1016/j.rce.2014.03.008", "24816042"]}, {"Citation": "Ferrario CM, Jessup J, Chappell MC, et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 2005;111(20):2605\u20132610. doi:10.1161/CIRCULATIONAHA.104.510461", "ArticleIdList": ["10.1161/CIRCULATIONAHA.104.510461", "15897343"]}, {"Citation": "Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054\u20131062. doi:10.1016/S0140-6736(20)30566-3", "ArticleIdList": ["10.1016/S0140-6736(20)30566-3", "PMC7270627", "32171076"]}, {"Citation": "Hassan SA, Sheikh FN, Jamal S, Ezeh JK, Akhtar A. Coronavirus (COVID-19): a review of clinical features, diagnosis, and treatment. Cureus. 2020;12(3):e7355. doi:10.7759/cureus.7355", "ArticleIdList": ["10.7759/cureus.7355", "PMC7170025", "32328367"]}, {"Citation": "Xu G, Yang Y, Du Y, et al. Clinical pathway for early diagnosis of COVID-19: updates from experience to evidence-based practice. Clin Rev Allergy Immunol. 2020. doi:10.1007/s12016-020-08792-8", "ArticleIdList": ["10.1007/s12016-020-08792-8", "PMC7180681", "32328954"]}, {"Citation": "Mills KT, Stefanescu A, He J. The global epidemiology of hypertension. Nat Rev Nephrol. 2020;16(4):223\u2013237. doi:10.1038/s41581-019-0244-2", "ArticleIdList": ["10.1038/s41581-019-0244-2", "PMC7998524", "32024986"]}, {"Citation": "Williams B, Mancia G, Spiering W, et al. 2018 practice guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC task force for the management of arterial hypertension. J Hypertens. 2018;36(12):2284\u20132309. doi:10.1097/HJH.0000000000001961", "ArticleIdList": ["10.1097/HJH.0000000000001961", "30379783"]}, {"Citation": "Hamming I, Cooper ME, Haagmans BL, et al. The emerging role of ACE2 in physiology and disease. J Pathol. 2007;212(1):1\u201311. doi:10.1002/path.2162", "ArticleIdList": ["10.1002/path.2162", "PMC7167724", "17464936"]}, {"Citation": "Lambert DW, Yarski M, Warner FJ, et al. Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005;280(34):30113\u201330119. doi:10.1074/jbc.M505111200", "ArticleIdList": ["10.1074/jbc.M505111200", "PMC8062222", "15983030"]}, {"Citation": "Palau V, Riera M, Soler MJ. ADAM17 inhibition may exert a protective effect on COVID-19. Nephrol Dial Transplant. 2020;35(6):1071\u20131072. doi:10.1093/ndt/gfaa093", "ArticleIdList": ["10.1093/ndt/gfaa093", "PMC7184459", "32291449"]}, {"Citation": "Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013280.e8. doi:10.1016/j.cell.2020.02.052", "ArticleIdList": ["10.1016/j.cell.2020.02.052", "PMC7102627", "32142651"]}, {"Citation": "Zores F, Rebeaud ME. COVID and the renin-angiotensin system: are hypertension or its treatments deleterious? Front Cardiovasc Med. 2020;7:71.", "ArticleIdList": ["PMC7191060", "32391384"]}, {"Citation": "Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586\u2013590. doi:10.1007/s00134-020-05985-9", "ArticleIdList": ["10.1007/s00134-020-05985-9", "PMC7079879", "32125455"]}, {"Citation": "Hoffmann M, Kleine-Weber H, Kr\u00fcger N, Mueller MA, Drosten C, P\u00f6hlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. BioRxiv. 2020."}, {"Citation": "Wang K, Chen W, Zhou Y-S, et al. SARS-CoV-2 invades host cells via a novel route: CD147-spike protein. bioRxiv. 2020;2020.03.14.988345. doi:10.1101/2020.03.14.988345", "ArticleIdList": ["10.1101/2020.03.14.988345"]}, {"Citation": "Donoghue M, Hsieh F, Baronas E, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1\u20139. doi:10.1161/01.res.87.5.e1", "ArticleIdList": ["10.1161/01.res.87.5.e1", "10969042"]}, {"Citation": "Batlle D, Wysocki J, Satchell K. Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy? Clin Sci (Lond). 2020;134(5):543\u2013545. doi:10.1042/CS20200163", "ArticleIdList": ["10.1042/CS20200163", "32167153"]}, {"Citation": "Turner AJ. ACE2 Cell Biology, Regulation, and Physiological Functions. The Protective Arm of the Renin Angiotensin System (RAS). 2015;185\u2013189. doi:10.1016/B978-0-12-801364-9.00025-0", "ArticleIdList": ["10.1016/B978-0-12-801364-9.00025-0"]}, {"Citation": "Hamming I, Timens W, Bulthuis MLC, Lely AT, Navis GJ, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203(2):631\u2013637. doi:10.1002/path.1570", "ArticleIdList": ["10.1002/path.1570", "PMC7167720", "15141377"]}, {"Citation": "Magrone T, Magrone M, Jirillo E. Focus on receptors for coronaviruses with special reference to angiotensin-converting enzyme 2 as a potential drug target \u2013 a perspective. Endocr Metab Immune Disord Drug Targets. 2020;20. doi:10.2174/1871530320666200427112902", "ArticleIdList": ["10.2174/1871530320666200427112902", "32338224"]}, {"Citation": "Li W, Moore MJ, Vasilieva N, et al. Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus. Nature. 2003;426(6965):450\u2013454. doi:10.1038/nature02145", "ArticleIdList": ["10.1038/nature02145", "PMC7095016", "14647384"]}, {"Citation": "Ksiazek TG, Erdman D, Goldsmith CS, et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med. 2003;348(20):1953\u20131966. doi:10.1056/NEJMoa030781", "ArticleIdList": ["10.1056/NEJMoa030781", "12690092"]}, {"Citation": "Lei C, Fu W, Qian K, et al. Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig. bioRxiv. 2020. doi:10.1101/2020.02.01.929976", "ArticleIdList": ["10.1101/2020.02.01.929976"]}, {"Citation": "Zhang Q, Cong M, Wang N, et al. Association of angiotensin-converting enzyme 2 gene polymorphism and enzymatic activity with essential hypertension in different gender: a case-control study. Medicine. 2018;97(42):e12917. doi:10.1097/MD.0000000000012917", "ArticleIdList": ["10.1097/MD.0000000000012917", "PMC6211892", "30335025"]}, {"Citation": "Chen YY, Zhang P, Zhou XM, et al. Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites. J Clin Pharm Ther. 2018;43(2):189\u2013195. doi:10.1111/jcpt.12625", "ArticleIdList": ["10.1111/jcpt.12625", "28895159"]}, {"Citation": "Burrell LM, Harrap SB, Velkoska E, Patel SK. The ACE2 gene: its potential as a functional candidate for cardiovascular disease. Clin Sci (Lond). 2013;124(2):65\u201376. doi:10.1042/CS20120269", "ArticleIdList": ["10.1042/CS20120269", "23013041"]}, {"Citation": "He J, Lu Y-P, Li J, et al. Fetal but not maternal Angiotensin Converting Enzyme (ACE)-2 gene Rs2074192 polymorphism is associated with increased risk of being a Small For Gestational Age (SGA) newborn. Kidney Blood Press Res. 2018;43(5):1596\u20131606. doi:10.1159/000494449", "ArticleIdList": ["10.1159/000494449", "30347406"]}, {"Citation": "Pan Y, Wang T, Li Y, et al. Association of ACE2 polymorphisms with susceptibility to essential hypertension and dyslipidemia in Xinjiang, China. Lipids Health Dis. 2018;17(1):241. doi:10.1186/s12944-018-0890-6", "ArticleIdList": ["10.1186/s12944-018-0890-6", "PMC6195726", "30342552"]}, {"Citation": "Lu N, Yang Y, Wang Y, et al. ACE2 gene polymorphism and essential hypertension: an updated meta-analysis involving 11,051 subjects. Mol Biol Rep. 2012;39(6):6581\u20136589. doi:10.1007/s11033-012-1487-1", "ArticleIdList": ["10.1007/s11033-012-1487-1", "22297693"]}, {"Citation": "Fan X, Wang Y, Sun K, et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clin Pharmacol Ther. 2007;82(2):187\u2013196. doi:10.1038/sj.clpt.6100214", "ArticleIdList": ["10.1038/sj.clpt.6100214", "17473847"]}, {"Citation": "Chen YY, Liu D, Zhang P, et al. Impact of ACE2 gene polymorphism on antihypertensive efficacy of ACE inhibitors. J Hum Hypertens. 2016;30(12):766\u2013771. doi:10.1038/jhh.2016.24", "ArticleIdList": ["10.1038/jhh.2016.24", "27121444"]}, {"Citation": "Vangjeli C, Dicker P, Tregouet D-A, Shields DC, Evans A, Stanton AV. A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project. J Renin Angiotensin Aldosterone Syst. 2011;12(4):504\u2013509. doi:10.1177/1470320311405557", "ArticleIdList": ["10.1177/1470320311405557", "21490025"]}, {"Citation": "Malard L, Kakinami L, O\u2019Loughlin J, et al. The association between the angiotensin-converting enzyme-2 gene and blood pressure in a cohort study of adolescents. BMC Med Genet. 2013;14:117. doi:10.1186/1471-2350-14-117", "ArticleIdList": ["10.1186/1471-2350-14-117", "PMC4228362", "24191856"]}, {"Citation": "Fan Z, Wu G, Yue M, et al. Hypertension and hypertensive left ventricular hypertrophy are associated with ACE2 genetic polymorphism. Life Sci. 2019;225:39\u201345. doi:10.1016/j.lfs.2019.03.059", "ArticleIdList": ["10.1016/j.lfs.2019.03.059", "30917908"]}, {"Citation": "Lieb W, Graf J, Gotz A, et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA augsburg echocardiographic substudy. J Mol Med (Berl). 2006;84(1):88\u201396. doi:10.1007/s00109-005-0718-5", "ArticleIdList": ["10.1007/s00109-005-0718-5", "16283142"]}, {"Citation": "Wang S-X, Tao T, Fu Z-Q, Xie X-Z, Wang H, Wang Y-T. Polymorphisms of angiotensin-converting enzyme 2 gene confer a risk to lone atrial fibrillation in Chinese male patients. Chin Med J (Engl). 2013;126(24):4608\u20134611.", "ArticleIdList": ["24342297"]}, {"Citation": "Wu X, Zhu B, Zou S, Shi J. The association between ACE2 gene polymorphism and the stroke recurrence in Chinese population. J Stroke Cerebrovasc Dis. 2018;27(10):2770\u20132780. doi:10.1016/j.jstrokecerebrovasdis.2018.06.001", "ArticleIdList": ["10.1016/j.jstrokecerebrovasdis.2018.06.001", "30056001"]}, {"Citation": "Liu D, Chen Y, Zhang P, et al. Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients. Medicine. 2016;95(24):e3876. doi:10.1097/MD.0000000000003876", "ArticleIdList": ["10.1097/MD.0000000000003876", "PMC4998461", "27310975"]}, {"Citation": "Adamzik M, Frey U, Sixt S, et al. ACE I/D but not AGT (\u22126)A/G polymorphism is a risk factor for mortality in ARDS. Eur Respir J. 2007;29(3):482\u2013488. doi:10.1183/09031936.00046106", "ArticleIdList": ["10.1183/09031936.00046106", "17107992"]}, {"Citation": "Saab YB, Gard PR, Overall ADJ. The geographic distribution of the ACE II genotype: a novel finding. Genet Res. 2007;89(4):259\u2013267. doi:10.1017/S0016672307009019", "ArticleIdList": ["10.1017/S0016672307009019", "18208631"]}, {"Citation": "Chiu RWK, Tang NLS, Hui DSC, et al. ACE2 gene polymorphisms do not affect outcome of severe acute respiratory syndrome. Clin Chem. 2004;50(9):1683\u20131686. doi:10.1373/clinchem.2004.035436", "ArticleIdList": ["10.1373/clinchem.2004.035436", "PMC7108155", "15331509"]}, {"Citation": "Goulter AB, Goddard MJ, Allen JC, Clark KL. ACE2 gene expression is up-regulated in the human failing heart. BMC Med. 2004;2(1):19. doi:10.1186/1741-7015-2-19", "ArticleIdList": ["10.1186/1741-7015-2-19", "PMC425604", "15151696"]}, {"Citation": "Delanghe JR, Speeckaert MM, De Buyzere ML. The host\u2019s angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections. Clin Chim Acta. 2020;505:192\u2013193. doi:10.1016/j.cca.2020.03.031", "ArticleIdList": ["10.1016/j.cca.2020.03.031", "PMC7102561", "32220422"]}, {"Citation": "Imai Y, Kuba K, Ohto-Nakanishi T, Penninger JM. Angiotensin-converting enzyme 2 (ACE2) in disease pathogenesis. Circ J. 2010;74(3):405\u2013410. doi:10.1253/circj.cj-10-0045", "ArticleIdList": ["10.1253/circj.cj-10-0045", "20134095"]}, {"Citation": "Stawiski EW, Diwanji D, Suryamohan K, et al. Human ACE2 receptor polymorphisms predict SARS-CoV-2 susceptibility. bioRxiv. 2020;2020.04.07.024752. doi:10.1101/2020.04.07.024752", "ArticleIdList": ["10.1101/2020.04.07.024752"]}, {"Citation": "Cao Y, Li L, Feng Z, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. Cell Discov. 2020;6(1):4\u20137. doi:10.1038/s41421-020-0147-1", "ArticleIdList": ["10.1038/s41421-020-0147-1", "PMC7040011", "32133153"]}, {"Citation": "Wu JT, Leung K, Bushman M, et al. Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China. Nat Med. 2020;26(4):506\u2013510. doi:10.1038/s41591-020-0822-7", "ArticleIdList": ["10.1038/s41591-020-0822-7", "PMC7094929", "32284616"]}, {"Citation": "Vickers C, Hales P, Kaushik V, et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277(17):14838\u201314843. doi:10.1074/jbc.M200581200", "ArticleIdList": ["10.1074/jbc.M200581200", "11815627"]}, {"Citation": "Serfozo P, Wysocki J, Gulua G, et al. Ang II (angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (Angiotensin-Converting Enzyme 2)-independent. Hypertens. 2020;75(1):173\u2013182. doi:10.1161/HYPERTENSIONAHA.119.14071", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.119.14071", "PMC7286421", "31786979"]}, {"Citation": "Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. doi:10.1016/S2213-2600(20)30116-8", "ArticleIdList": ["10.1016/S2213-2600(20)30116-8", "PMC7118626", "32171062"]}, {"Citation": "Zhang P, Zhu L, Cai J, et al. Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19. Circ Res. 2020. doi:10.1161/CIRCRESAHA.120.317134", "ArticleIdList": ["10.1161/CIRCRESAHA.120.317134", "PMC7265882", "32302265"]}, {"Citation": "Li XC, Zhang J, Zhuo JL. The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol Res. 2017;125(Pt A):21\u201338. doi:10.1016/j.phrs.2017.06.005", "ArticleIdList": ["10.1016/j.phrs.2017.06.005", "PMC5607101", "28619367"]}, {"Citation": "Caldeira D, Alarcao J, Vaz-Carneiro A, Costa J. Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis. BMJ. 2012;345(jul11 1):e4260. doi:10.1136/bmj.e4260", "ArticleIdList": ["10.1136/bmj.e4260", "PMC3394697", "22786934"]}, {"Citation": "Wirtz H, Hasenclever D, Schwabe K, et al. ACE inhibitor for lung protection during mechanical ventilation for acute lung injury \u2013 results of the double-blind, placebo controlled, randomised ACEmeVENT pilot study. In: B16. Critical Care: New Insights From Clinical Trials. American Thoracic Society International Conference Abstracts American Thoracic Society; 2017:A2895\u2013A2895. doi:10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2895", "ArticleIdList": ["10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A2895"]}, {"Citation": "Kim J, Choi SM, Lee J, et al. Effect of renin-angiotensin system blockage in patients with acute respiratory distress syndrome: a retrospective case control study. Korean J Crit Care Med. 2017;32(2):154\u2013163. doi:10.4266/kjccm.2016.00976", "ArticleIdList": ["10.4266/kjccm.2016.00976", "PMC6786717", "31723629"]}, {"Citation": "Sun ML, Yang JM, Sun YP, Su GH. Inhibitors of RAS might be a good choice for the therapy of COVID-19 pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E014. doi:10.3760/cma.j.issn.1001-0939.2020.0014", "ArticleIdList": ["10.3760/cma.j.issn.1001-0939.2020.0014", "32061198"]}, {"Citation": "Peng YD, Meng K, Guan HQ, et al. Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48:E004. doi:10.3760/cma.j.cn112148-20200220-00105", "ArticleIdList": ["10.3760/cma.j.cn112148-20200220-00105", "32120458"]}, {"Citation": "Danser AHJ, Batenburg WW, van den Meiracker AH, Danilov SM. ACE phenotyping as a first step toward personalized medicine for ACE inhibitors. Why does ACE genotyping not predict the therapeutic efficacy of ACE inhibition? Pharmacol Ther. 2007;113(3):607\u2013618. doi:10.1016/j.pharmthera.2006.12.001", "ArticleIdList": ["10.1016/j.pharmthera.2006.12.001", "17257685"]}, {"Citation": "Sommerstein R, Kochen MM, Messerli FH, Gr\u00e4ni C. Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect? J Am Heart Assoc. 2020;9(7):e016509. doi:10.1161/JAHA.120.016509", "ArticleIdList": ["10.1161/JAHA.120.016509", "PMC7428596", "32233753"]}, {"Citation": "Liu Z, Xiao X, Wei X, et al. Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2. J Med Virol. 2020;92(6):595\u2013601. doi:10.1002/jmv.25726", "ArticleIdList": ["10.1002/jmv.25726", "PMC7228221", "32100877"]}, {"Citation": "Mancia G, Rea F, Ph D, et al. Renin\u2013angiotensin\u2013aldosterone system blockers and the risk of Covid-19. N Engl J Med. 2020:1\u201310. doi:10.1056/NEJMoa2006923", "ArticleIdList": ["10.1056/NEJMoa2006923", "PMC7206933", "32356627"]}, {"Citation": "Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;1\u20138. doi:10.1056/NEJMoa2007621", "ArticleIdList": ["10.1056/NEJMoa2007621", "PMC7206931", "32356626"]}, {"Citation": "Reynolds HR, Adhikari S, Pulgarin C, et al. Renin\u2013angiotensin\u2013aldosterone system inhibitors and risk of Covid-19. N Engl J Med. 2020:1\u20138. doi:10.1056/NEJMoa2008975", "ArticleIdList": ["10.1056/NEJMoa2008975", "PMC7206932", "32356628"]}, {"Citation": "de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. European Society of Cardiology.13.03.2020"}, {"Citation": "Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. American College of Cardiology. 17.03.2020", "ArticleIdList": ["PMC7234783", "32439095"]}, {"Citation": "U.S. National Library of Medicine. 2020. \nAvailable from:\nClinicalTrials.Gov. ClinicalTrials.gov. https://clinicaltrials.gov. Accessed June7, 2020."}, {"Citation": "University Hospital Strasbourg France. Efficacy of hydroxychloroquine, telmisartan and azithromycin on the survival of hospitalized elderly patients with COVID-19 (COVID-aging). 2020. \nAvailable from:\nClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04359953?term=arb&cond=covid-19&draw=5&rank=36. Accessed June7, 2020."}]}], "History": [{"Year": "2020", "Month": "5", "Day": "6"}, {"Year": "2020", "Month": "6", "Day": "19"}, {"Year": "2020", "Month": "8", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "9", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "8", "Day": "14", "Hour": "6", "Minute": "0"}, {"Year": "2020", "Month": "7", "Day": "21"}], "PublicationStatus": "epublish", "ArticleIdList": ["32764907", "PMC7382582", "10.2147/CIA.S261516", "261516"]}}]}